Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
NASA shares first photos of Earth taken by Artemis II- Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- New movies to watch this weekend: See 'Wake Up Dead Man: A Knives Out Mystery' in theaters, rent 'Bugonia,' stream 'Caught Stealing' on Netflix
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- 5 Superstar Couples That Motivate Relationship Objectives
- Etymological Investigation Disclosed: A Survey of \Dominating New Tongues\ Language Learning Application
- Kenmore East reacts to their best overall delegation award at WNY Model United Nations General Assembly competition
- Figure out How to Augment Your Rooftop Substitution Speculation
